Executive readout · one minute
Call research workspace
Read the call alongside every captured source. Audio, transcript, slides and SEC filings stay in one workspace.
ACAD
$28.24
-0.49%
ACAD · Acadia Pharmaceuticals Inc
$28.24
-0.14 (-0.49%)
At close · Aug 14
Market Cap
$4.87B
Shares
172.31M
All earnings calls
Earnings call · FY2026 Q2
Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026
Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026
Forward guidance
5 guided metrics
Management's latest ranges and targets are included below.
Research coverage
2 live sources
Switch sources without leaving this page or losing your listening position.
Revenue
$307.96M
+16.4% YoY
Diluted EPS
$0.18
+12.5% YoY
Net income
$31.50M
+18.1% YoY
Research materials
Open the source you need; every reader stays inside this workspace.
Forward guidance
From the 8-K filed Aug 4, 2026.
| Metric | Period | Guided | Basis |
|---|---|---|---|
|
Total revenues
Full Year 2026
|
$1.24B – $1.3B | GAAP | |
|
NUPLAZID net product sales
Full Year 2026
|
$760M – $790M | GAAP | |
|
R&D expense
Full Year 2026
|
$355M – $380M | GAAP | |
|
SG&A expense
Full Year 2026
|
$660M – $700M | GAAP | |
|
DAYBUE (including all forms of trofinetide) global net product s
Full Year 2026
|
$480M – $510M | GAAP |
SEC filing · Item 2.02
8-K earnings release
Filed Aug 4, 2026 · complete as-filed document
SEC periodic report
10-Q report
Filed Aug 5, 2026 · complete as-filed document